MX2021014163A - Forma cristalina de bromuro de sofpironio y metodo para su preparacion. - Google Patents
Forma cristalina de bromuro de sofpironio y metodo para su preparacion.Info
- Publication number
- MX2021014163A MX2021014163A MX2021014163A MX2021014163A MX2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- sofpironium bromide
- preparation
- diastereomer
- sofpironium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporciona un cocristal que contiene el diastereómero 1'R y el diastereómero 1'S de bromuro de sofpironio en una relación de 1:3 (Forma CO), una mezcla de cristales (por ejemplo, la Forma B) que contiene la Forma CO y una forma cristalina del diastereómero 1'R (Forma MN), y un método para preparar bromuro de sofpironio, que es adecuado para la fabricación de la mezcla de cristales. La Forma CO y una forma cristalina de bromuro de sofpironio que contiene la Forma CO (por ejemplo, la Forma B) tienen una estabilidad superior sin propiedades higroscópicas y, por consiguiente, pueden usarse preferentemente como materia prima de medicamentos. 1. Una forma cristalina estable de bromuro de sofpironio adecuada para el uso como sustancia farmacológica en un medicamento, dicha forma cristalina comprende un compuesto que se muestra como la fórmula I-a (ver Fórmula) dicha forma cristalina se caracteriza por mostrar picos a 7,1 ± 0,1, 21,4 ± 0,1, 22,3 ± 0,1 y 24,5 ± 0,1 como ángulos de difracción 2? en el espectro de difracción de rayos X en polvo, dicha forma cristalina es la Forma MN cristalina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851880P | 2019-05-23 | 2019-05-23 | |
| PCT/JP2020/020210 WO2020235665A1 (en) | 2019-05-23 | 2020-05-22 | Crystalline form of sofpironium bromide and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014163A true MX2021014163A (es) | 2022-01-04 |
Family
ID=72146250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014163A MX2021014163A (es) | 2019-05-23 | 2020-05-22 | Forma cristalina de bromuro de sofpironio y metodo para su preparacion. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20220298108A1 (es) |
| EP (1) | EP3972955A4 (es) |
| JP (2) | JP6748329B1 (es) |
| KR (1) | KR20220011671A (es) |
| CN (1) | CN114008023B (es) |
| AU (1) | AU2020277881A1 (es) |
| BR (1) | BR112021023241A2 (es) |
| CA (1) | CA3139948A1 (es) |
| CL (1) | CL2021003047A1 (es) |
| CO (1) | CO2021017456A2 (es) |
| IL (1) | IL288285A (es) |
| MX (1) | MX2021014163A (es) |
| SG (1) | SG11202111678WA (es) |
| TW (2) | TWI838531B (es) |
| WO (1) | WO2020235665A1 (es) |
| ZA (1) | ZA202109514B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4002383A3 (en) | 2020-11-13 | 2022-08-03 | Tokyo Institute of Technology | Information processing device, information processing method, recording medium recording information processing program, and information processing system |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| JP5257073B2 (ja) * | 2005-11-10 | 2013-08-07 | ボーダー、ニコラス・エス | ソフト型抗コリン作動性エステル |
| US7399861B2 (en) * | 2005-11-10 | 2008-07-15 | Bodor Nicholas S | Soft anticholinergic esters |
| MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
| US9512166B2 (en) * | 2012-09-05 | 2016-12-06 | Amri Ssci, Llc | Cocrystals of progesterone |
| US20150259283A1 (en) * | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| US10906871B2 (en) * | 2016-08-02 | 2021-02-02 | Dermira, Inc. | Processes for making, and methods of using, glycopyrronium compounds |
-
2020
- 2020-05-22 JP JP2020089283A patent/JP6748329B1/ja active Active
- 2020-05-22 MX MX2021014163A patent/MX2021014163A/es unknown
- 2020-05-22 EP EP20809754.3A patent/EP3972955A4/en active Pending
- 2020-05-22 SG SG11202111678WA patent/SG11202111678WA/en unknown
- 2020-05-22 WO PCT/JP2020/020210 patent/WO2020235665A1/en active Application Filing
- 2020-05-22 TW TW109117164A patent/TWI838531B/zh active
- 2020-05-22 CA CA3139948A patent/CA3139948A1/en active Pending
- 2020-05-22 US US17/611,158 patent/US20220298108A1/en active Pending
- 2020-05-22 AU AU2020277881A patent/AU2020277881A1/en active Pending
- 2020-05-22 CN CN202080034880.8A patent/CN114008023B/zh active Active
- 2020-05-22 BR BR112021023241A patent/BR112021023241A2/pt unknown
- 2020-05-22 KR KR1020217041385A patent/KR20220011671A/ko unknown
- 2020-05-22 TW TW112144978A patent/TW202411205A/zh unknown
- 2020-08-06 JP JP2020133620A patent/JP2020189856A/ja active Pending
- 2020-11-25 US US17/105,376 patent/US11566000B2/en active Active
-
2021
- 2021-06-30 US US17/364,445 patent/US11584715B2/en active Active
- 2021-11-18 CL CL2021003047A patent/CL2021003047A1/es unknown
- 2021-11-21 IL IL288285A patent/IL288285A/en unknown
- 2021-11-24 ZA ZA2021/09514A patent/ZA202109514B/en unknown
- 2021-12-20 CO CONC2021/0017456A patent/CO2021017456A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020235665A1 (en) | 2020-11-26 |
| CA3139948A1 (en) | 2020-11-26 |
| US20210395197A1 (en) | 2021-12-23 |
| US11566000B2 (en) | 2023-01-31 |
| TW202411205A (zh) | 2024-03-16 |
| JP2020189856A (ja) | 2020-11-26 |
| IL288285A (en) | 2022-01-01 |
| CL2021003047A1 (es) | 2022-09-20 |
| EP3972955A4 (en) | 2023-07-05 |
| ZA202109514B (en) | 2023-12-20 |
| JP2020189839A (ja) | 2020-11-26 |
| AU2020277881A1 (en) | 2021-12-09 |
| SG11202111678WA (en) | 2021-11-29 |
| TWI838531B (zh) | 2024-04-11 |
| CN114008023A (zh) | 2022-02-01 |
| CO2021017456A2 (es) | 2022-01-17 |
| US20220298108A1 (en) | 2022-09-22 |
| JP6748329B1 (ja) | 2020-08-26 |
| US20210171460A1 (en) | 2021-06-10 |
| TW202110796A (zh) | 2021-03-16 |
| EP3972955A1 (en) | 2022-03-30 |
| BR112021023241A2 (pt) | 2022-01-04 |
| KR20220011671A (ko) | 2022-01-28 |
| CN114008023B (zh) | 2024-02-09 |
| US11584715B2 (en) | 2023-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004014902A8 (en) | Compounds having an activity at metabotropic glutamate receptors | |
| JOP20210241A1 (ar) | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان | |
| MX2021015936A (es) | Metodos para preparar acido bempedoico y composiciones del mismo. | |
| TW200613243A (en) | Novel compounds | |
| GEP20094664B (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| MY139303A (en) | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
| MXPA05013752A (es) | Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos. | |
| NO20051223L (no) | Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5. | |
| MY138086A (en) | Novel urea derivative as vanilloid receptor-1 antagonist | |
| MXPA05010712A (es) | Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| GEP20094576B (en) | New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| SE0302192D0 (sv) | Novel compounds | |
| GEP20043362B (en) | Novel $G(Y)Crystalline Form of Perindopril Tert- Butylamine Salt, Preparation Method, and Pharmaceutical Compositions Containing Same | |
| ZA202109514B (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| TW200505505A (en) | Process for modifying drug crystal formation | |
| JO2493B1 (en) | New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| HK1066545A1 (en) | Novel amlodipine camsylate and method for preparing thereof | |
| MX2008001018A (es) | Derivados de n-(arilalquil)-1h-pirrolopiridina-2-carboxamida, su preparacion y su aplicacion en terapeutica. | |
| GB0109122D0 (en) | Novel compounds | |
| MY145166A (en) | Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof | |
| FI3873894T3 (fi) | Bcl-2-inhibiittorin uusi suola, siihen liittyvä kidemuoto, menetelmä sen valmistamiseksi ja sitä sisältäviä farmaseuttisia koostumuksia | |
| JPS55147258A (en) | 44aryloxyy and 44arylthioo33phenylpiperidine derivatives* their manufacture and their use as medicine | |
| DK1532098T3 (da) | Fremgangsmåde til fremstilling af nitrooxyderivater af naproxen |